Regulatory Sourcebook eBook
Read the article:
Serialization and Aggregation from a Manufacturing Perspective
Read the eBook:
BioPharm International October 2021 eBook
For some manufacturers, the goal was to be fully compliant with the DSCSA, including both serialization and aggregation, from day one.
Enacted by Congress on Nov. 27, 2013, the US Drug Supply Chain Security Act (DSCSA) is intended to build a more secure supply chain in the United States with the ability to identify and trace drug products and limit exposure to counterfeit, contaminated, and otherwise harmful drugs. Everyone in the pharmaceutical supply chain has had to pivot to meet the DSCSA requirements, including manufacturers, repackagers, wholesale distributors, dispensers, and third-party logistics providers (trading partners). Manufacturers, specifically, have had to incorporate serialization into their manufacturing and packaging lines and will eventually also have to incorporate aggregation as well. However, FDA won’t require aggregation compliance until Nov. 27, 2023, which was delayed from 2019.
Read the article:
Serialization and Aggregation from a Manufacturing Perspective
Read the eBook:
BioPharm International October 2021 eBook
Meg Rivers is a senior editor for Pharmaceutical Technology, Pharmaceutical Technology Europe, and BioPharm International.
BioPharm International
eBook: Regulatory Sourcebook
October 2021
Pages: 10-13
When referring to this article, please cite it as M. Rivers, “Serialization and Aggregation from a Manufacturing Perspective," BioPharm International’s Regulatory Sourcebook eBook (October 2021).
almost 4 years ago
Industry Organizations Assist Pharma During the Pandemic and Beyondalmost 4 years ago
NIST Proposes Clarifications to Bayh-Dole March-in Rights Regulationsalmost 4 years ago
How Artificial Intelligence Impacts the Global Regulatory Environmentalmost 4 years ago
Selecting the Right CMC Strategy for Biologicsalmost 4 years ago
The Evolving Biosimilar Approachalmost 4 years ago
The Real Danger of Substandard and Counterfeit COVID-19 Vaccinesalmost 4 years ago
Collecting Industry’s Thoughts on FDA FARS ReportStay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.